{"filing":{"accession_number":"0001835268-26-000034","cik":"0001835268","ticker":"CNTB","company_name":"Connect Biopharma Holdings Ltd","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"cntb-20260915.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000034/cntb-20260915.htm"},"events":[{"id":33458,"run_id":30764,"accession_number":"0001835268-26-000034","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Connect Biopharma announced positive topline results from its Phase 2 Seabreeze STAT asthma study of rademikibart on September 15, 2026, showing statistically significant improvements in lung function (FEV1) and a 66% reduction in treatment failure rate, though the primary endpoint missed statistical significance. This material clinical milestone was disclosed via press release and represents a significant development in the company's pipeline progress and regulatory pathway.","company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36908,"accession_number":"0001835268-26-000034","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Connect Biopharma announced topline results from its Phase 2 Seabreeze STAT Asthma study of rademikibart on September 15, 2026, disclosed via press release (Exhibit 99.1) under Item 7.01. While this is clinical trial data rather than financial earnings, it represents a material disclosure of significant clinical milestone results—a 66% reduction in treatment failure and statistically significant lung function improvement—that would affect a reasonable investor's assessment of the company's pipeline progress and regulatory pathway. For clinical-stage biopharmaceutical companies, positive Phase 2 data announcements function analogously to earnings releases in signaling material business developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:07:46.886606+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36909,"accession_number":"0001835268-26-000034","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Connect Biopharma announced positive topline results from its Phase 2 Seabreeze STAT asthma study of rademikibart, showing statistically significant improvements in lung function (FEV1) and a 66% reduction in treatment failure rate, though the primary endpoint missed statistical significance. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would inform investor assessment of the drug candidate's development trajectory and regulatory pathway forward, but it does not fit the earnings_release category (which applies to financial results) nor any other specific event type. The disclosure centers on a significant operational/clinical development milestone rather than financial results, M\u0026A activity, or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:07:46.886606+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36908,"accession_number":"0001835268-26-000034","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Connect Biopharma announced topline results from its Phase 2 Seabreeze STAT Asthma study of rademikibart on September 15, 2026, disclosed via press release (Exhibit 99.1) under Item 7.01. While this is clinical trial data rather than financial earnings, it represents a material disclosure of significant clinical milestone results—a 66% reduction in treatment failure and statistically significant lung function improvement—that would affect a reasonable investor's assessment of the company's pipeline progress and regulatory pathway. For clinical-stage biopharmaceutical companies, positive Phase 2 data announcements function analogously to earnings releases in signaling material business developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:07:46.886606+00:00","company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","filing_date":"2026-09-15"},{"id":36909,"accession_number":"0001835268-26-000034","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Connect Biopharma announced positive topline results from its Phase 2 Seabreeze STAT asthma study of rademikibart, showing statistically significant improvements in lung function (FEV1) and a 66% reduction in treatment failure rate, though the primary endpoint missed statistical significance. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would inform investor assessment of the drug candidate's development trajectory and regulatory pathway forward, but it does not fit the earnings_release category (which applies to financial results) nor any other specific event type. The disclosure centers on a significant operational/clinical development milestone rather than financial results, M\u0026A activity, or governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:07:46.886606+00:00","company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","filing_date":"2026-09-15"}]}